Market closedNon-fractional

Ocuphire Pharma/OCUP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ocuphire Pharma

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Ticker

OCUP

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Farmington Hills, United States

Employees

14

Ocuphire Pharma Metrics

BasicAdvanced
$40M
Market cap
-
P/E ratio
-$0.50
EPS
0.37
Beta
-
Dividend rate
$40M
0.37
8.959
8.689
-9.14%
-15.60%
-25.89%
1.798
0.83
0.83
-10.741
-54.30%
-156.67%
-62.20%

What the Analysts think about Ocuphire Pharma

Analyst Ratings

Majority rating from 4 analysts.
Buy

Ocuphire Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-417.64% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
6.25%
Net income
-$7.1M
51.06%
Profit margin
-417.64%
42.18%

Ocuphire Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 116.42%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.24
$0.25
-$0.21
-$0.29
-
Expected
-$0.23
-$0.22
-$0.05
-$0.13
-$0.24
Surprise
6.19%
-212.61%
300.00%
116.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ocuphire Pharma stock?

Ocuphire Pharma (OCUP) has a market cap of $40M as of July 06, 2024.

What is the P/E ratio for Ocuphire Pharma stock?

The price to earnings (P/E) ratio for Ocuphire Pharma (OCUP) stock is 0 as of July 06, 2024.

Does Ocuphire Pharma stock pay dividends?

No, Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Ocuphire Pharma dividend payment date?

Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders.

What is the beta indicator for Ocuphire Pharma?

Ocuphire Pharma (OCUP) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Ocuphire Pharma stock

Buy or sell Ocuphire Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing